Lymphocyte/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B

Chia Yun Wu, Liang Tsai Hsiao, Tzeon Jye Chiou, Jyh Pyng Gau, Jin Hwang Liu, Yuan Bin Yu, Yi Tsui Wu, Chia Jen Liu, Yu Chung Huang, Man Hsin Hung, Po Min Chen, Yi Hsiang Huang, Cheng Hwai Tzeng

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Lymphocyte/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B'. Together they form a unique fingerprint.

Immunology and Microbiology

Pharmacology, Toxicology and Pharmaceutical Science